Top cited articles

To celebrate another year of high quality, cutting edge content published in Lupus Science & Medicine®, we have shortlisted the most cited papers of the past 2 years.

2020

Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr mice
APR 2020 10.1136/lupus-2020-000387

Prediction of prognosis and renal outcome in lupus nephritis
FEB 2020 10.1136/lupus-2020-000389

Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
JAN 2020 10.1136/lupus-2019-000362

Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease
JUNE 2020 10.1136/lupus-2020-000394

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
JUNE 2020 10.1136/lupus-2019-000373

Towards a practical management of fatigue in systemic lupus erythematosus
NOV 2020 10.1136/lupus-2020-000441

Anti-Mullerian hormone in African-American women with systemic lupus erythematosus
NOV 2020 10.1136/lupus-2020-000439

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
JUL 2020 10.1136/lupus-2020-000399

Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE
JUN 2020 10.1136/lupus-2020-000398

Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus
JUN 2020 10.1136/lupus-2019-000375</span

2019

Interferon pathway in SLE: one key to unlocking the mystery of the disease
AUG 2019 10.1136/lupus-2018-000270

Type I interferons in host defence and inflammatory diseases
MAY 2019 10.1136/lupus-2019-000336

10 most important contemporary challenges in the management of SLE
JAN 2019 10.1136/lupus-2018-000303

Changing paradigms in the treatment of systemic lupus erythematosus
FEB 2019 10.1136/lupus-2018-000310

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE
MAR 2019 10.1136/lupus-2019-000318

First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
NOV 2019 10.1136/lupus-2019-000354

Development of a systemic lupus erythematosus cardiovascular risk equation
OCT 2019 10.1136/lupus-2019-000346

Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study
APR 2019 10.1136/lupus-2018-000298

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
SEP 2019 10.1136/lupus-2019-000349

SLE: reconciling heterogeneity
FEB 2019 10.1136/lupus-2018-000280